CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
The PDE-4 Inhibitor Roflumilast reduces weight gain, enhances insulin sensitivity and prevents hepatic steatosis in mice by increasing mitochondrogenesis
DOI 10.1055/s-0034-1375058
Bibliografische Angaben
Nachweis in CareLit
Autor:innenF Kahles, J Möllmann, C Bäck, A Liberman, K Hess, HM Findeisen, S Krüger, C Lebherz, F Tacke, N Marx, M Lehrke
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe05/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Purpose: Roflumilast is a new PDE-4 inhibitor with anti-inflammatory properties which is clinically used to reduce the exacerbation of chronic bronchitis. Interestingly, roflumilast was also found to reduce body weight and improve glucose metabolism of humans with yet elusive mechanism. Methods and Results: We therefore treated C57BL/6 mice on western diet (n = 15/group) for a period of 12 weeks with roflumilast (ad…
Zitieren
Zitierempfehlung
F Kahles, J Möllmann, C Bäck, A Liberman, K Hess, HM Findeisen, S Krüger, C Lebherz, F Tacke, N Marx, M Lehrke (2014) The PDE-4 Inhibitor Roflumilast reduces weight gain, enhances insulin sensitivity and prevents hepatic steatosis in mice by increasing mitochondrogenesis. Diabetologie und Stoffwechsel (05). https://doi.org/10.1055/s-0034-1375058
Mit CareLit weiterarbeiten